(Q34007678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Paul Declerck

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

M L V Hendrickx

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A DE Winter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

K Buelens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Compernolle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Hassanzadeh-Ghassabeh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A Gils

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thrombosis and Haemostasis

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

2268-2277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21883886%20AND%20SRC:MED&resulttype=core&format=json

Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines.

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Naturally occurring antibodies devoid of light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Potent enzyme inhibitors derived from dromedary heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Generation of a stable activated thrombin activable fibrinolysis inhibitor variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Clinical perspectives and therapeutics of thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Enzyme-linked immunosorbent assays using immune complexes for the diagnosis of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X

Strongin VivoMaturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04495.X